Genomic Health Announces Presentation of Two Large Studies at the 2018 San Antonio Breast Cancer Symposium, Reinforcing Real-world Value of the Oncotype DX Breast Recurrence Score® Test

REDWOOD CITY, Calif., Nov. 19, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present results from two large studies of the Oncotype DX Breast Recurrence Score^® test at the 2018 San Antonio Breast Cancer Symposium^® (SABCS), which will be held December 4-8. The study findings reinforce the value of the Oncotype DX^® test in optimizing treatment and outcomes in patients with both node-negative and node-positive early-stage breast cancer. Presentations include:

• Results from a large population-based clinical outcomes study based on the Surveillance, Epidemiology, and End Results (SEER) registry program of the National Cancer Institute (NCI), the premier source of cancer statistics in the United States. To provide long-term (nine years) real-world evidence for both prognosis and chemotherapy benefit, the study assessed breast cancer-specific survival in patients with node-negative and node-positive disease who were treated based on their Oncotype DX Breast Recurrence Score test results.
• Analysis of 500 early-stage breast cancer patients age 40 or younger to further the understanding of the value of the Oncotype DX test in guiding chemotherapy treatment decisions. The analysis is based on a multi-center prospective cohort study led by Dana-Farber Cancer Institute investigators in Boston.

Complete results from both studies will be announced in accordance with the SABCS embargo policy. Following are details for the two poster presentations:

• Abstract: P3-11-02
  Poster: Breast cancer specific mortality in patients with node-negative and node-positive breast cancer guided by the 21-gene assay: A SEER-genomic population-based study
  Authors: Hortobagyi GN, Shak S, Sledge GW Jr., Winer EP, Albain KS, Mamounas EP, Jakubowski DM, Petkov VI, Wolmark N
  Location: Hall 1
  Date and Time: Thursday, December 6, 7-9 a.m. CST
• Abstract: P2-08-07
  Poster: Prognostic impact of the 21-gene Recurrence Score assay among young women with node-negative and node-positive early-stage breast cancer
  Authors: Poorvu PD, Gelber SI, Rosenberg SM, Ruddy KJ, Tamimi RM, Collins LC, Peppercorn J, Schapira L, Borges VF, Come SE, Warner E, Jakubowski DM, Russell C, Winer EP, Partridge AH
  Location: Hall 1
  Date and Time: Thursday, December 6, 7-9 a.m. CST

About Oncotype DX^®
The Oncotype DX^® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. The company's flagship product, the Oncotype DX breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. Additionally, the test predicts the likelihood of recurrence in a pre-invasive form of breast cancer called DCIS. With more than 950,000 patients tested in more than 90 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about Oncotype DX tests, visit www.OncotypeDX.com or www.MyBreastCancerTreatment.org.

About Genomic Health 
Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that help optimize cancer care, including addressing the overtreatment of the disease, one of the greatest issues in healthcare today. With its Oncotype IQ^® Genomic Intelligence Platform, the company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of clinical and genomic big data into actionable results for treatment planning throughout the cancer patient journey, from diagnosis to treatment selection and monitoring. The Oncotype IQ portfolio of genomic tests and services currently consists of the company's flagship line of Oncotype DX^® gene expression tests that have been used to guide treatment decisions for more than 950,000 cancer patients worldwide. Genomic Health is expanding its test portfolio to include additional liquid- and tissue-based tests, including the recently launched Oncotype DX^® AR-V7 Nucleus Detect™ test. The company is based in Redwood City, California, with international headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: our business model; the applicability of clinical study results to actual outcomes; the impact of results from clinical studies on market adoption of Oncotype DX tests; unanticipated costs or delays in research and development efforts; and other risks and uncertainties set forth in our filings with the Securities and Exchange Commission, including our most recent report on Form 10-Q for the quarter ended September 30, 2018. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Breast Recurrence Score, DCIS Score, Genomic Prostate Score, Oncotype DX AR-V7 Nucleus Detect, and Oncotype IQ are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.

GHDX-B

SOURCE Genomic Health, Inc.

Related Links

https://www.genomichealth.com